{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:41:42Z","timestamp":1790844102611,"version":"4.1.0"},"reference-count":47,"publisher":"Impact Journals, LLC","issue":"45","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,3]]},"DOI":"10.18632\/oncotarget.20094","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T19:31:25Z","timestamp":1502307085000},"page":"79864-79875","source":"Crossref","is-referenced-by-count":20,"title":["Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies"],"prefix":"10.18632","volume":"8","author":[{"given":"Paolo F.","family":"Caimi","sequence":"first","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, Ohio, USA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, Ohio, USA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem M.","family":"William","sequence":"additional","affiliation":[{"name":"Division of Hematology. The Ohio State University Medical School, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, Ohio, USA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Rochester, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pink","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, Ohio, USA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, Ohio, USA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanton L.","family":"Gerson","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, Ohio, USA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,8,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Schiffer","year":"2000","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Zinzani","year":"2010","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hon.2151","article-title":"Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin\u2019s lymphoma: experience on 143 patients","volume":"33","author":"Pileri","year":"2015","journal-title":"Hematol Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Unterhalt","year":"2004","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24391","article-title":"High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients","volume":"91","author":"Sessarego","year":"2016","journal-title":"Am J Hematol"},{"key":"6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL","volume":"347","author":"Hiddemann","year":"1996","journal-title":"Lancet"},{"key":"7","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.bbmt.2016.07.006","article-title":"Fludarabine\/Busulfan versus Fludarabine\/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma","volume":"22","author":"Armand","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"8","doi-asserted-by":"crossref","first-page":"16617","DOI":"10.1016\/S0021-9258(17)46267-3","article-title":"Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity","volume":"265","author":"Plunkett","year":"1990","journal-title":"J Biol Chem"},{"key":"9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","article-title":"Cellular and clinical pharmacology of fludarabine","volume":"41","author":"Plunkett","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.leu.2402114","article-title":"Nucleoside analogues: mechanisms of drug resistance and reversal strategies","volume":"15","author":"Dumontet","year":"2001","journal-title":"Leukemia"},{"key":"11","first-page":"1731","article-title":"Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes","volume":"2","author":"Plunkett","year":"1996","journal-title":"Clin Cancer Res"},{"key":"12","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Plunkett","year":"2001","journal-title":"Clin Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2003-09-3236","article-title":"Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response","volume":"104","author":"Staudt","year":"2004","journal-title":"Blood"},{"key":"14","first-page":"3204","article-title":"Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine","volume":"9","author":"Plunkett","year":"2003","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3233(04)69001-2","article-title":"Base excision repair","volume":"69","author":"Verdine","year":"2004","journal-title":"Adv Protein Chem"},{"key":"16","doi-asserted-by":"crossref","first-page":"21203","DOI":"10.1074\/jbc.273.33.21203","article-title":"Mammalian abasic site base excision repair. Identification of the reaction sequence and rate-determining steps","volume":"273","author":"Wilson","year":"1998","journal-title":"J Biol Chem"},{"key":"17","doi-asserted-by":"crossref","first-page":"15230","DOI":"10.1074\/jbc.274.21.15230","article-title":"The type of DNA glycosylase determines the base excision repair pathway in mammalian cells","volume":"274","author":"Dogliotti","year":"1999","journal-title":"J Biol Chem"},{"key":"18","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/nar\/30.8.1817","article-title":"A quantitative model of human DNA base excision repair. I. Mechanistic insights","volume":"30","author":"Wilson","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/35077232","article-title":"Genome maintenance mechanisms for preventing cancer","volume":"411","author":"Hoeijmakers","year":"2001","journal-title":"Nature"},{"key":"20","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1074\/jbc.M611295200","article-title":"Coordination of steps in single-nucleotide base excision repair mediated by apurinic\/apyrimidinic endonuclease 1 and DNA polymerase beta","volume":"282","author":"Wilson","year":"2007","journal-title":"J Biol Chem"},{"key":"21","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1158\/0008-5472.CAN-05-0715","article-title":"The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death","volume":"65","author":"Sobol","year":"2005","journal-title":"Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/0008-5472.CAN-10-3213","article-title":"Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair","volume":"71","author":"Sobol","year":"2011","journal-title":"Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/cddis.2011.135","article-title":"Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair","volume":"3","author":"Liu","year":"2012","journal-title":"Cell Death Dis"},{"key":"24","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1038\/leu.2010.166","article-title":"Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia","volume":"24","author":"Liu","year":"2010","journal-title":"Leukemia"},{"key":"25","first-page":"2908","article-title":"Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents","volume":"5","author":"Gerson","year":"1999","journal-title":"Clin Cancer Res"},{"key":"26","first-page":"2985","article-title":"Base excision repair as a therapeutic target in colon cancer","volume":"8","author":"Gerson","year":"2002","journal-title":"Clin Cancer Res"},{"key":"27","first-page":"838","article-title":"Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization","volume":"63","author":"Kinsella","year":"2003","journal-title":"Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1158\/1535-7163.955.3.8","article-title":"Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells","volume":"3","author":"Kelley","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/1078-0432.CCR-06-1920","article-title":"Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide","volume":"13","author":"Kelley","year":"2007","journal-title":"Clin Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1158\/1078-0432.CCR-06-1595","article-title":"Combined Treatment with Temozolomide and Methoxyamine: Blocking Apurininc\/Pyrimidinic Site Repair Coupled with Targeting Topoisomerase II\u03b1","volume":"13","author":"Liu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.bloodjournal74119","article-title":"Fludarabine: a new agent with major activity against chronic lymphocytic leukemia","volume":"74","author":"McCredie","year":"1989","journal-title":"Blood"},{"key":"32","first-page":"2719","article-title":"Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5\u2019-monophosphate in non-Hodgkin\u2019s lymphoma: prospective comparison of response with deoxycytidine kinase activity","volume":"47","author":"Grever","year":"1987","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Travade","year":"2001","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1200\/jco.2010.28.15_suppl.2576","article-title":"Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer","volume":"28","author":"Leigh","year":"2010","journal-title":"J Clin Oncol"},{"key":"35","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/jco.2015.33.15_suppl.2558","article-title":"Phase I clinical trial temozolomide and methoxyamine (TRC-102) in patients","volume":"33","author":"Beatty","year":"2015","journal-title":"J Clin Oncol"},{"key":"36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2012.070755","article-title":"Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia","volume":"98","author":"Ysebaert","year":"2013","journal-title":"Haematologica"},{"key":"37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00177259","article-title":"Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study","volume":"8","author":"Salmon","year":"1990","journal-title":"Invest New Drugs"},{"key":"38","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s10637-012-9876-9","article-title":"A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors","volume":"31","author":"Theuer","year":"2013","journal-title":"Invest New Drugs"},{"key":"39","doi-asserted-by":"crossref","first-page":"e90675","DOI":"10.1371\/journal.pone.0090675","article-title":"Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies","volume":"9","author":"Furukawa","year":"2014","journal-title":"PLoS One"},{"key":"40","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2014.55.8262","article-title":"Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician","volume":"32","author":"Flynn","year":"2014","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.blre.2015.12.002","article-title":"Targeted therapies for CLL: Practical issues with the changing treatment paradigm","volume":"30","author":"O\u2019Brien","year":"2016","journal-title":"Blood Rev"},{"key":"42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Kochling","year":"2016","journal-title":"Lancet Oncol"},{"key":"43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Lister","year":"2007","journal-title":"J Clin Oncol"},{"key":"44","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Beksac","year":"2006","journal-title":"Leukemia"},{"key":"45","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Kipps","year":"2008","journal-title":"Blood"},{"key":"46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchromb.2012.05.036","article-title":"Development and validation of an LC-MS\/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial","volume":"901","author":"Xu","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/mutage\/gen015","article-title":"Statistical issues in the use of the comet assay","volume":"23","author":"Omori","year":"2008","journal-title":"Mutagenesis"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.20094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T22:47:46Z","timestamp":1692917266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.20094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,9]]},"references-count":47,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2017,10,3]]}},"alternative-id":["20094","29108368"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.20094","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,9]]}}}